Claim
In a retrospective metastatic prostate-cancer cohort, among cases classified as IMF6-high, androgen-receptor pathway inhibitor treatment was associated with lower treatment-failure risk than taxane treatment (HR 0.21, 95% CI 0.05–0.79, P = 0.021).
32 words; atomic claims are usually under 25a comma-separated series may list several propositionsTopics
Medicine · 1efd24fe Health · 1efd24fe
Assessment
Supported
Main unresolved issue: 3 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:3d5173cc-1aca-84d1-9ee1-41233f2eb2a6
Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.Every quoted passage was confirmed on the page when Galedra fetched it.
Why?
Strongest counted support: The study reports lower treatment-failure risk for ARPI than taxane among IMF6-high cases with the stated confidence interval and P value. weight 2.000000 evidence
Suppressed as dependent: The excerpt directly reports the IMF6-high ARPI-versus-taxane hazard ratio, confidence interval, and P value.
Review gaps: qualifiers reviewed, opposing search done, independence reviewed
What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Unresolved.
0.8808 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability MEDIUM · 3 sources, 1 independent lineage
How the number was reached
| Link | Working | Weight | Counted as |
|---|---|---|---|
| ad24d942 qualify | relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 1.800000 | 0.000000 (non directional) |
| cc8a9f3c support | relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 2.000000 | 2.000000 |
| 95208c8e support | relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 2.000000 | 0.000000 (dependent strongest only, kept cc8a9f3c) |
prior 0.50 → log-odds 0.000000 + 2.000000 (the counted weights) = 2.000000 → probability 0.8808
Your view
Registered views
Nobody has registered a view yet.
Checked as part of
- “In a retrospective metastatic prostate-cancer cohort, among cases classified as IMF6-high, androgen-receptor pathway inhibitor treatment was associated with...” · 1 claim · 29 September 2026
- “A 2026 Nature study integrated mutational signatures across prostate-cancer genomes to characterize mutational processes and explore clinical associations.” · 2 claims · 29 September 2026
Evidence for
-
From Integrated signatures define mutational processes in prostate cancer Read 2026-09-29 Relevance DIRECT Steps 0 Counted
The passage directly reports the treatment comparison and effect estimate.
-
From Integrated signatures define mutational processes in prostate cancer Read 2026-09-29 Relevance DIRECT Steps 0 Counted
The passage explicitly states the treatment comparison and effect estimate.
Evidence against
None.
Qualifications
-
From Integrated signatures define mutational processes in prostate cancer Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Narrows the association to the study's second-line mCRPC setting and notes treatment-history and comparison limitations.
Suppressed as dependent
| Evidence | Group | Kept instead |
|---|---|---|
| 971c88a4 | cc8a9f3c |
Inferences
Concluded from
None.
Used as a premise in
None.
Threads
None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.
Claim edges
None. Edges are stored and displayed; v0.1 does not propagate probability across them.
Review checklist
Review checks: 1 of 4
| Check | Done | By |
|---|---|---|
| qualifiers reviewed | no | |
| opposing search done | no | |
| independence reviewed | no | |
| primary source reviewed | yes | cc8a9f3c, 95208c8e |
Summary
Supported. The main support is: The study reports lower treatment-failure risk for ARPI than taxane among IMF6-high cases with the stated confidence interval and P value. af46f92c
1 further item repeats the same origin and is not independent evidence. 971c88a4
Qualifier: The treatment association was evaluated in second-line metastatic castration-resistant disease, with pre-enrolment records less complete and no overall TTF difference between therapies. c4c3f722
Review checks: 1 of 4. coverage:3d5173cc-1aca-84d1-9ee1-41233f2eb2a6
Contribution history
| seq | event | detail |
|---|---|---|
| 15009 | APPENDED | |
| 15010 | ACCEPT | AUTOMATIC_AFTER_VALIDATION |
| 15019 | LINK_EVIDENCE | by 1efd24fe (accepted) |
| 15023 | TASK_RESULT | by 1efd24fe (accepted) |
| 15312 | LINK_EVIDENCE | by 1efd24fe (accepted) |
Score trace
{
"claim": "3d5173cc-1aca-84d1-9ee1-41233f2eb2a6",
"links": [
{
"link": "201ffd25-d45a-85e2-a2cc-bf72ad24d942",
"group": null,
"reason": "non_directional",
"edition": "NAMED_OR_UNRELATED",
"evidence": "7aa4bc7b-8c3f-8167-8bcb-8fe7c4c3f722",
"direction": "QUALIFY",
"magnitude": "1.800000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "DIRECT_TEXT",
"source_type": "SECONDARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "0.000000",
"interpretive_steps": 0
},
{
"link": "7b18b773-428e-8599-abc3-6a3acc8a9f3c",
"group": null,
"edition": "NAMED_OR_UNRELATED",
"evidence": "8e71d72b-210f-8525-960d-32a4af46f92c",
"direction": "SUPPORT",
"magnitude": "2.000000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "MEASUREMENT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "2.000000",
"interpretive_steps": 0
},
{
"kept": "7b18b773-428e-8599-abc3-6a3acc8a9f3c",
"link": "fcd37bdb-a3dd-84f4-9488-e62495208c8e",
"group": null,
"reason": "dependent_strongest_only",
"edition": "NAMED_OR_UNRELATED",
"evidence": "80d84592-cc4b-8297-b157-b700971c88a4",
"direction": "SUPPORT",
"magnitude": "2.000000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "MEASUREMENT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "0.000000",
"interpretive_steps": 0
}
],
"model": "ledger-default@0.3.0",
"prior": "0.50",
"variants": {
"spread": "0.1287",
"permissive": "0.9309",
"conservative": "0.8022"
},
"code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
"contested": false,
"stability": "MEDIUM",
"claim_type": "QUANTITATIVE",
"config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
"probability": "0.8808",
"provisional": true,
"evidence_sum": "2.000000",
"snapshot_seq": 15313,
"prior_log_odds": "0.000000",
"support_groups": 1,
"model_dependent": false,
"review_coverage": "0.25",
"truth_evaluable": true,
"assessment_state": "SUPPORTED",
"review_checklist": {
"qualifiers_reviewed": {
"by": [],
"ok": false
},
"opposing_search_done": {
"by": [],
"ok": false
},
"independence_reviewed": {
"by": [],
"ok": false
},
"primary_source_reviewed": {
"by": [
"7b18b773-428e-8599-abc3-6a3acc8a9f3c",
"fcd37bdb-a3dd-84f4-9488-e62495208c8e"
],
"ok": true
}
},
"contradict_groups": 0,
"rounding_boundary": false,
"posterior_log_odds": "2.000000",
"not_applicable_reason": null,
"independence_unreviewed": 3
}